SCHEMBL5237992

SCHEMBL5237992

COc1ccc(N2CCCNCC2)cc1

nearest known ligand 0.86

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 4/20 0.86
HTR3A P46098 3/20 0.86
HTR3E A5X5Y0 2/20 0.86
HTR3B O95264 2/20 0.86
HTR3D Q70Z44 2/20 0.86
HTR3C Q8WXA8 2/20 0.86
SIGMAR1 Q99720 1/20 0.86
CHRNB2 P17787 3/20 0.66
CHRNA4 P43681 3/20 0.66
HTR1A P08908 2/20 0.60
HTR1D P28221 2/20 0.60
HTR1B P28222 1/20 0.60
HTR7 P34969 1/20 0.60
HTR2B P41595 1/20 0.60
LTA4H P09960 4/20 0.56
HTR2C P28335 1/20 0.54
TGFBR1 P36897 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2410870 0.93 ADRB1 (1.00) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL234280 0.93 ADRB1 (1.00) ADRB1HTR3AHTR3EHTR3BHTR3D
Bromide SCHEMBL11070661 0.91 ADRB1 (0.96) ADRB1HTR3AHTR3EHTR3BHTR3D
Hydrochloric Acid SCHEMBL2302729 0.91 ADRB1 (0.96) ADRB1HTR3AHTR3EHTR3BHTR3D
Hydrochloric Acid SCHEMBL1724680 0.91 ADRB1 (0.96) ADRB1HTR3AHTR3EHTR3BHTR3D
Piperazine SCHEMBL8590918 0.91 ADRB1 (0.96) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL9058690 0.88 ADRB1 (0.89) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL2881283 0.88 ADRB1 (0.89) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL5686228 0.86 ADRB1 (0.86) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL7171062 0.86 ADRB1 (0.86) ADRB1HTR3AHTR3EHTR3BHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130005710-A1 AMINOPYRIDINE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-03 US disclosed
EP-2502909-A1 AMINOPYRIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2012-09-26 EP disclosed
EP-1592426-B1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2007-12-19 EP disclosed
US-20070219234-A1 Thienopyridine Derivatives SANKYO COMPANY, LIMITED (JP) 2007-09-20 US disclosed
EP-1764367-A1 THIENOPYRIDINE DERIVATIVES Sankyo Company, Limited (JP) 2007-03-21 EP disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005710-A1 AMINOPYRIDINE DERIVATIVE DCX, NR0B1, NR4A1 ADRB1 126/4885HTR3A 432/4885HTR3E 1569/4885
US-20070219234-A1 Thienopyridine Derivatives RASGRP1, NRAS, HRH3 ADRB1 241/4885HTR3A 3772/4885HTR3E 4205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.